Latest Uterine fibroids Stories
SAN DIEGO, Oct. 31, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2011. For the third quarter of 2011, the Company reported net income of $31.4 million, or $0.56 per fully diluted share outstanding, compared to net income of $3.3 million, or $0.06 per fully diluted share outstanding, for the same period in 2010. For the nine months ended September 30, 2011, the Company reported a net income of $36.2...
Researchers have found the first, firm evidence that fibroids are associated with recurrent miscarriages. They have also discovered that if they removed the fibroids that distorted the inside of the womb, the risk of miscarriage in the second trimester of pregnancy was reduced dramatically – to zero. The study, which is published online in Europe's leading reproductive medicine journal Human Reproduction today (Wednesday), is the culmination of 20 years of investigation into recurrent...
SAN DIEGO, Sept. 27, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that an elagolix podium presentation has been accepted for the scientific program at the 2011 Annual Meeting of the American Society for Reproductive Medicine, to be held October 15-19, 2011 in Orlando, Florida. This annual meeting draws over 4,000 experts from around the world to address current topics related to human reproduction. "We are very pleased to participate in the annual...
ANDOVER, Mass., Sept. 21, 2011 /PRNewswire/ -- Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, today announced the introduction of its TRUCLEAR(TM) SIM Morcellation Simulator, a highly-realistic, hands-on simulator designed to improve training for gynecologists who perform hysteroscopic morcellation, a procedure to remove intrauterine polyps and fibroids. In 2011 alone, over one million women will seek treatment for abnormal uterine bleeding due to...
SAN DIEGO, Sept. 13, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that Abbott has started a Phase II clinical trial to evaluate elagolix, a next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonist, in the treatment of uterine fibroids. The initiation of this trial triggered a $10 million milestone payment from Abbott to the Company. "We are pleased that our collaboration has reached this important milestone with elagolix now being...
Uterine leiomyomas, also called fibroids, cause a very significant burden to women's health. They are benign tumors that occur in 60% of women by the age of 45 years and cause symptoms such as abdominal pain and discomfort, and abnormal bleeding, in about half of the cases. Fibroids are also an important cause of infertility. These tumors are the most common medical reason for hysterectomy. Considering the clinical importance of fibroids, relatively little has been known about the...
PAOLI, Pa., June 27, 2011 /PRNewswire/ -- A radiologic technology, which functions like a 'human GPS system,' and provides more precise results while using less radiation, is being used to treat patients with symptomatic uterine fibroids exclusively at Paoli Hospital. Dr. Atul Gupta, director of interventional radiology, is treating patients as part of a first-ever clinical trial. To view the multimedia assets associated with this release, please click...
CHARLOTTESVILLE, Va., June 23, 2011 /PRNewswire-USNewswire/ -- Medical researchers have a critical role to play in gaining optimal health insurance reimbursement for MR-guided focused ultrasound. As Susan Klees, Director of Patient Access for the Focused Ultrasound Surgery Foundation, reports, "Scientific evidence is the key driver for reimbursement, and it all begins with the way studies are designed. Today, research priorities must be grounded in sound science as well as the realities of...
CHARLOTTESVILLE, Va., June 22, 2011 /PRNewswire/ -- On June 12, 2011, viewers of the CBS Evening News learned about Stephanie Small's gripping story. Suffering from a large uterine fibroid, the 27-year-old was treated last December as part of a MR-guided focused ultrasound clinical trial at the University of Virginia in Charlottesville. Small says her focused ultrasound treatment changed her life. She experienced symptom relief within a few days and reports that her quality of life has...
CHARLOTTESVILLE, Va., June 21, 2011 /PRNewswire-USNewswire/ -- What's easier: gaining regulatory approval for a new medical device, or convincing insurers to cover the treatments it provides? According to Susan Klees of the Focused Ultrasound Surgery Foundation, many experts say regulatory approval is the easier task. An interview with Klees is one of the reimbursement-related articles featured in the June 2011 issue of the foundation's online newsletter. As Director of Patient Access, she...
